MDY Healthcare Plc

Alan MacKayChairman

Alan was appointed Chairman of MDY in April 2009. He is an independent adviser to private equity funds and was formerly a partner at 3i Investments plc and a director of several specialist investors including Atle Industri AB and 3TS Capital Partners Oy. He is currently an independent non-executive director of US based vaccine specialist Phibro Animal Health Corporation. His track record of successful healthcare investments includes many small high growth pharma and medtech businesses, as well as major international healthcare service companies such as Quintiles. He is a member of the Institute of Directors.

Grahame CookNon-executive Director

Grahame Cook was appointed to the board in May 2010. Grahame is a chartered accountant and has more than 20 years' experience in investment banking in London, Switzerland and Germany. He was a director at Barclays de Zoete Wedd until 1995, then a Managing Director at UBS Investment Banking until 1998 following which he was CEO of West LB Panmure until 2003.

Grahame has significant experience of capital raising, capital structuring and mergers and acquisitions. Since 2003, he has been a non-executive director of a number of companies, including Minoan Group plc, a resort developer, and Antisoma plc, a biotech company specialising in novel drugs for the treatment of cancer. Grahame is the chairman of Sinclair Pharma plc, a skin and mouth disease specialist and the chairman of Fulcrum Pharma PLC, a provider of strategic drug development and regulatory services.

Martin HuntNon-executive Director

Martin Hunt was appointed to the board in May 2010. Martin has spent 28 years in the medtech industry working for both multi-nationals and small to medium size enterprises. He spent 10 years at American Cyanamid in sales and marketing positions in the fields of pharmaceuticals, wound closure and latterly, ophthalmic surgery as marketing director for Europe, Middle East & Africa. Martin spent five years at Bristol-Myers Squibb in wound care and stoma therapy as Regional Operations Director and then VP Sales, Europe between 1994 and 1996.

Martin was a founder of a start-up in the IV infusion field before joining Tissue Science (TSL), a company with a novel collagen-based technology, as CEO in 1999. Under Martin's leadership, TSL was successfully admitted to AIM in 2001 and then sold to Covidien in 2008 at a substantial premium to the share price reflecting significant growth in revenues at TSL. Since leaving TSL, Martin has continued to be involved in medtech innovations with a number of non-executive director and advisor roles. These include Orthox Limited, an Oxford spin-out in the field of cartilage repair where he is chairman; Director and advisor at Trophos SA, a French biotech addressing CNS diseases; Programme Director at i4i (a National Institute for Health Research early stage medtech funding programme) and a Venture Partner at H2O Venture Partners in Oxford.

Dr David WongExecutive

David was previously a director of MDY Healthcare and has been involved with the business since 1998. In 1992 he founded Medical Consultants and Management Limited, an investment company specialising in medical and bioscience companies. He received a degree in dentistry from Guy's Hospital Medical School in 1976 and went on to found a group of dental surgery clinics, which were sold in 1988. He also built up and sold a food business to Slater Foods PLC where he became a director.

Louisa HellierGeneral Counsel & Company Secretary

Louisa was appointed General Counsel and Company Secretary in September 2006. Prior to that she worked in the Healthcare Corporate Finance Group at Nomura International which she joined in 1997. Prior to that she was a solicitor in the corporate department at Allen & Overy where she qualified in 1996 having graduated from Oxford University. Louisa is also a director of Trust William Limited, an investee company of MDY Healthcare.